1. Scrip
  2. >>Therapy Areas
  3. >>Sensory

Iveric Bio Building Ophthalmology Commercial Team Ahead Of First Launch

 
• By Jessica Merrill

CEO Glenn Sblendorio talked to Scrip about the company's plans to transition into a commercial-stage company after completing an NDA submission for its geographic atrophy drug in December.

building blocks
Iveric Bio is building commercially • Source: Shutterstock

Iveric Bio is building a commercial organization ahead of the potential launch of its complement C5 inhibitor avacincaptad pegol (ACP) for geographic atrophy later this year. CEO Glenn Sblendorio talked to Scrip in an interview at the J.P. Morgan Healthcare Conference in January about the firm’s transition to a commercial-stage company after finalizing a new drug application for the therapy at the end of 2022.

"Our plan has been, in the US, to launch on our own," Sblendorio said. "About a year ago, I started to build what I believe is a world-class retina team, commercial and medical," he added

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Sensory

Merck & Co. CMO Barr On Breaking Into Immunology And Ophthalmology

 
• By Jessica Merrill

Chief medical officer Eliav Barr discussed Merck’s investment in new therapeutic areas and business development in an interview with Scrip.

In Brief: US FDA Rejects Regeneron’s Bid to Extend Eylea HD Dosing

 
• By Sushmita Panda

Regeneron is disappointed by the knock-back for longer dosing intervals for its high-dose version of Eylea, but its supplemental application for a more commercially important shorter four-week regimen has received a priority review.

Outlook Holds Out Hope For Wet AMD Approval Despite Phase III Topline Miss

 
• By Alaric DeArment

The company said the NORSE EIGHT trial of ONS-5010 did not meet the primary endpoint of showing noninferiority to ranibizumab, but it still plans to file for US FDA approval.

GSK’s Linerixibat GLISTENs In PBC Itching

 
• By Elizabeth Cairns

But differences in trial design means it is hard to handicap GSK’s product against Mirum’s volixibat.

More from Therapy Areas

Leo Roars To A Profit In Q1 As Adbry Grows In US

 
• By Kevin Grogan

The Danish firm's atopic dermatitis drug is holding its own despite strong competition from Sanofi/Regeneron’s Dupixent.

Multiple Launches Help Lilly’s Japan Growth

 
• By Ian Haydock

Lilly saw solid growth for its business in Japan last year on the back of several new launches and is building its obesity and Alzheimer's portfolios in the country.

Novo Nordisk Looks To Septerna For Oral Obesity Options

 
• By Mary Jo Laffler

Deal Snapshot: The Danish drugmaker is partnering with GPCR drug discovery expert Septerna to develop multiple small molecules for cardiometabolic targets.